Evidence map›Paper›PMID 34224057›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Long noncoding RNA MGC27382 inhibits proliferation and metastasis of non-small cell lung cancer cells via down-regulating AKT/GSK3β pathway.

Q Li, S Li, L Niu, S Yang, H Niu, C Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Q LiDepartment of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
S LiDepartment of Gastroenterology, People's Hospital of Weihaiwei, Weihai, China.
L NiuDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
S YangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
H NiuCentral Research Laboratory, The Second Hospital of Shandong University, Jinan, China.
C ChengDepartment of Thoracic Surgery, Qilu Hospital, Shandong University, 107 Wenhua Xi Road, Jinan, China. chengchuanle@sdu.edu.cn.ORCID http://orcid.org/0000-0002-4645-8928
Second Hospital of Shandong University · CNQilu Hospital of Shandong University · CNShandong Provincial Hospital · CNUnion Hospital · CNWeihai Municipal Hospital · CN

Funding

National Natural Science Foundation of China 82002540Postdoctoral Research Foundation of China 2018M630786
6 · The paper itself

Abstract

purposePersistent abnormal proliferation and long distant metastasis of tumors contribute to high mortality rate in non-small cell lung cancer (NSCLC) patients. Strategies that prevent NSCLC proliferation and/or metastasis have been studied but still need to be further explored. Numerous studies have proved the diversity functions of long noncoding RNAs (lncRNAs) exerted in cancer, including NSCLC. In this study, we aim to identify and investigate the role of novel lncRNAs in NSCLC progression.

methodsRNA sequence data were retrieved from the Cancer Genome Atlas (TCGA), differentially expressed lncRNAs (DElncRNAs) were screened out based on the R language, then real-time PCR experiment was introduced to detect the DElncRNA expression levels. A series of experiments including MTT, cell cycle, transwell, and wound healing assays were employed to explore the effect of DElncRNA MGC27382 on cell proliferation and invasion ability.

resultsWe detected that DElncRNA MGC27382 is down-regulated in NSCLC tissues and cells. Overexpression of MGC27382 prevented NSCLC cell proliferation via down-regulating cyclin D1 and cyclin E. Moreover, wound healing and transwell assays indicated that the ability of cell invasion and migration could be impaired when cells were treated with MGC27382 overexpression. Further studies demonstrated that MGC27382-mediated inhibition on NSCLC progression can be impaired by LY294002, which is a frequently used inhibitor of AKT/GSK3β pathway.

conclusionMGC27382 is down-regulated in NSCLC. It exerts an inhibitory role in NSCLC development through suppressing the AKT/GSK3β pathway. Our results indicate that the lncRNA MGC27382 might be a tumor-suppressor gene in NSCLC. Overexpression of MGC27382 is thought to be a potential strategy for overcoming NSCLC progression.

Indexed as

Gene Expression Regulation, NeoplasticApoptosisBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell CycleCell MovementCell ProliferationCyclin EGlycogen Synthase Kinase 3 betaHumansLung NeoplasmsNeoplasm MetastasisOncogene ProteinsPrognosisProto-Oncogene Proteins c-aktRNA, Long NoncodingBiomarkers, TumorCCNE1 protein, humanCyclin EGlycogen Synthase Kinase 3 betaOncogene ProteinsProto-Oncogene Proteins c-aktRNA, Long NoncodingCancer developmentMigrationPrognosisProgressionTCGA

Identifiers

PMID34224057
OpenAlexW3182209772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.